Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Cascadia Commences First Drill Test of 1,065 g/t Gold Outcrop at Catch Property (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Fennec Pharmaceuticals Ord Shs
T.FRX
Alternate Symbol(s):
FENC
Healthcare
Biotechnology
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK...
. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:FRX)
New Post
View:
Posts & Comments
Threaded Posts
(10)
•••
MikeTester
X
Post by
MikeTester
on Jan 24, 2025 1:34pm
Fennec Pharmaceuticals Inc. (FENC): Capitalizing on the Unme
Looks like FENC is making serious moves in the pediatric cancer space. $22M in net product sales for 9 months is impressive, especially being their first commercial year with PEDMARK. FDA approval in
...more
(2269)
•••
Betteryear2
X
Post by
Betteryear2
on Mar 21, 2024 11:36am
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing
...more
(44)
•••
willyk3
X
Post by
willyk3
on Mar 17, 2024 10:06pm
Norgine exclusive agreement
for Europe. Should be a good day for Fennec !!! Still waiting on that buyout
(44)
•••
willyk3
X
Comment by
willyk3
on Oct 17, 2022 8:41am
RE:Pedmark approved
Pedmark commercially available as of today!!! Great news for everyone involved..investors and patients alike.
(44)
•••
willyk3
X
Post by
willyk3
on Sep 21, 2022 8:24am
Pedmark approved
by the US FDA. Finally!!!! Now ....about that takeout??
(2269)
•••
Betteryear2
X
Post by
Betteryear2
on Aug 01, 2022 10:14am
Fennec Pharmaceuticals Up to $45 M Investment From Petrichor
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to
...more
(44)
•••
willyk3
X
Comment by
willyk3
on Dec 13, 2021 8:05am
RE:RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?
The obvious solution at this stage is to just sell the darn company (at a discount) to a real pharmaceautical company who has the capability to complete the process
(44)
•••
willyk3
X
Comment by
willyk3
on Dec 09, 2021 9:46am
RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?
Absolute dud The fact that they failed at the manufacturing revisions shows that they and their mfg partner are incompetant at this aspect of the process. Wonder who that is ?
...more
(4)
•••
AviseAnalytics
X
Post by
AviseAnalytics
on Dec 09, 2021 7:08am
IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?
$FENC Fennec Pharmaceuticals (NASDAQ:FENC), a "specialty pharmaceutical company", received a CRL from the FDA for its New Drug Application (NDA) for PEDMARK™ (sodium
...more
(44)
•••
willyk3
X
Post by
willyk3
on Sep 27, 2021 5:30pm
11.50/18.00
Thats a heck of a spread on the bid ask? Has my machine gone bonkers?
(44)
•••
willyk3
X
Comment by
willyk3
on Jun 22, 2021 8:13am
RE:Times a wasting
Resubmission is in! Is there anyone out there to notice? Guess we still have to hope that they dont fail....with the FDA I am never confident of anything. Buyout coming???
(44)
•••
willyk3
X
Post by
willyk3
on Mar 20, 2021 12:49pm
Times a wasting
No news at all. Wonder whats up with that resubmission? Shouldnt financials be out for this quarter? I thought they were reasonably cashed up but lack of any communication from the company is
...more
(4)
•••
neuralProphet
X
Comment by
neuralProphet
on Mar 01, 2021 12:44pm
RE:Silent board
Not too may shares outstanding + less than avg 100k shares trading in CanadaUS in total = not enough retail owners to light up a Stockhouse board. Yahoo forum has a bit more action. Revenue wise
...more
(22)
•••
stockfy
X
Comment by
stockfy
on Jan 28, 2021 5:10pm
RE:Silent board
Any idea when FRX will report the first revenue? Just a rough estimate. Thanks.
(22)
•••
stockfy
X
Post by
stockfy
on Jan 28, 2021 5:09pm
Silent board
Why is this board so silent? Aren't any retail investors in FRX?
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >